79 terms you will meet reading about peptides (chemistry, pharmacology, manufacturing, evidence and regulation), each with why it actually matters.
A single amino acid unit once it has been joined into a chain, having lost the
water molecule consumed in bond formation. Chains are described by residue count
("a 34-residue peptide") and by the one- or three-letter codes for each residue in order.
Why it matters: Residue count and order are the molecule's identity. Two products
with the same marketing name but a one-residue difference are different compounds with
potentially different behaviour.
The amide linkage between the carboxyl group of one amino acid and the amino group
of the next, formed by eliminating water. It is planar, rigid, and rotationally
restricted, which constrains the shapes a chain can adopt.
Why it matters: This bond is what proteolytic enzymes in the gut and bloodstream are
built to cut. Its vulnerability is the single biggest reason most peptides cannot be
swallowed and do not last long in circulation.
The two ends of a peptide chain: the N-terminus carries a free amino group, the
C-terminus a free carboxyl group. Sequences are conventionally written N-terminus first,
left to right.
Why it matters: Terminal chemistry is where most stability modifications are made, and
where enzymes most often start cutting. "Same sequence, different ends" is a real and
common difference between products.
A conventional, not chemical, distinction: chains up to roughly 50 residues are
usually called peptides, longer ones proteins. Nothing physical changes at the boundary.
Why it matters: The word "peptide" is often used in marketing to imply something small,
gentle and natural. It implies none of those things.
Building a chain one residue at a time on an insoluble resin bead, so unreacted
reagents can be washed away after every cycle. The finished chain is cleaved from
the resin at the end.
Why it matters: SPPS is efficient but not perfect: every cycle has a yield below 100%,
and the errors accumulate into the impurity profile that a purity figure is meant to
describe.
A by-product in which one or more residues failed to couple, producing a chain that is
correct except for a missing unit. It is the characteristic impurity of synthetic peptides.
Why it matters: Deletion sequences are structurally similar to the target and can
co-elute with it, so they inflate apparent purity unless the analytical method was
developed to separate them.
A stereoisomer differing at exactly one chiral centre. In peptides this usually means one
residue has flipped from L to D during synthesis.
Why it matters: Epimers have identical molecular mass, so mass spectrometry alone
cannot detect them. Only a chiral or high-resolution chromatographic method can.
The unintended conversion of an L-residue to a mixture of L and D during coupling or
cleavage, promoted by heat, base and certain activating reagents.
Why it matters: It is the invisible quality failure: the mass is right, the
sequence is right, and the activity is wrong.
Joining a peptide's ends, or two side chains, to form a ring: via an amide bond,
a disulfide, or a synthetic staple.
Why it matters: Cyclisation is one of the few reliable ways to make a peptide resist
enzymatic degradation and hold a defined shape, which is why several orally viable
peptide drugs are cyclic.
A covalent bond between two cysteine residues that locks a specific three-dimensional
fold. Many natural peptide hormones depend on one or more.
Why it matters: Disulfides can form in the wrong pairing during manufacture,
producing a mis-folded isomer with the correct mass and the wrong function.
Replacing the terminal carboxyl group with an amide. Many natural peptides are amidated
in the body as a final activation step.
Why it matters: For some hormones the non-amidated form is close to inactive. "Free
acid" versus "amide" is a genuine, activity-determining difference between two products
sold under one name.
Attaching a fatty acid chain, usually via a linker, so the peptide binds reversibly to
serum albumin and is released slowly.
Why it matters: This is the design change that turned several once-daily peptide
hormones into once-weekly medicines. It is protein engineering, not a natural property.
Attaching polyethylene glycol to increase a molecule's effective size, slowing
filtration by the kidney and shielding it from enzymes.
Why it matters: It extends duration at the cost of added immunogenic and
manufacturing complexity, and it changes the molecule that any prior evidence was
generated on.
Freeze-drying: the frozen solution is placed under vacuum so ice sublimes directly to
vapour, leaving a dry cake. It is the standard way peptides are stabilised for storage
and transport.
Why it matters: A lyophilised solid is far more stable than a solution, which is why
peptides ship dry. It also means the visible amount in a vial is mostly bulking agent and
salt, not peptide.
Peptides are purified as salts. Trifluoroacetate (TFA) is the residue of the standard
purification solvent; acetate is the salt form used for pharmaceutical products because
it is better tolerated.
Why it matters: TFA is cytotoxic in cell culture at achievable concentrations and can
confound experimental results, and a TFA salt is not a pharmaceutical-grade form.
A certificate that does not state the salt form is incomplete.
The proportion of a vial's stated mass that is actually the peptide, after subtracting
water, counter-ions and excipients. Typically 70-85% for a TFA salt.
Why it matters: It is routinely omitted from unlicensed product labelling, so the
number on the vial can overstate the actual quantity of compound by a fifth or more.
A protein that changes state when a specific molecule binds it, converting that binding
into a cellular signal.
Why it matters: Almost every peptide claim reduces to a receptor claim. Asking
"which receptor, and what is the evidence it engages it in humans?" collapses most
marketing copy immediately.
The seven-transmembrane receptor family that most therapeutic peptides act on,
signalling through intracellular G proteins and β-arrestins.
Why it matters: GPCRs desensitise and internalise, which is why "more" is not reliably
"more effect". They can also be biased: two agonists at the same receptor may
preferentially drive different downstream pathways and so produce genuinely different
effect and side-effect profiles. "It hits the same receptor" is not equivalence.
A ligand that binds a receptor and activates it, producing the same class of response
as the natural ligand.
Why it matters: The default assumption behind most peptide claims. Whether a given
compound is actually an agonist at human receptors, at achievable concentrations, is
usually the unexamined question.
A ligand that activates a receptor but cannot produce the full maximal response, even at
saturating concentration.
Why it matters: In the presence of the full natural agonist, a partial agonist can
reduce net signalling. The same molecule can therefore look stimulating in one context
and blunting in another.
A ligand that occupies a receptor without activating it, preventing the natural ligand
from acting.
Why it matters: Same pocket, opposite outcome. Sequence similarity to a hormone tells
you nothing about whether a compound will mimic or block it.
How tightly a ligand binds its target, expressed as the dissociation constant, the
concentration at which half the receptors are occupied. Lower means tighter.
Why it matters: Affinity is frequently quoted as though it were effect size. It says
nothing about whether binding produces a response, or whether that concentration is
reachable in a body.
The size of the response a bound ligand produces, independent of how tightly it binds.
Why it matters: A compound can have exceptional affinity and zero efficacy. Affinity
and efficacy are separate axes, and marketing routinely conflates them.
The concentration required to produce a given effect. A more potent compound needs less
to reach the same effect, not a larger maximum effect.
Why it matters: "More potent" is regularly presented as "works better". It means
"works at a lower concentration", which is a manufacturing and dosing property, not a
clinical benefit.
The concentration producing half of a compound's own maximal effect in a given assay.
The standard summary of potency.
Why it matters: EC50 is assay-specific. A nanomolar EC50 in an engineered cell line
overexpressing a receptor may be irrelevant to concentrations achievable in human plasma.
The rapid loss of responsiveness that follows sustained receptor stimulation, mediated by
receptor phosphorylation and uncoupling from downstream signalling.
Why it matters: It is the built-in reason continuous stimulation of a hormone pathway
tends to produce diminishing returns, and why pulsatile natural hormone release exists at
all. Early strong effects that fade over hours or days are a pharmacological pattern, not
evidence of a bad batch, and they are frequently misread as the latter.
The longer-term reduction in the number of receptors on a cell surface after prolonged
stimulation, via internalisation and degradation.
Why it matters: Recovery takes days rather than minutes, so effects on the underlying
system can outlast the compound in circulation by a long margin.
A compound that prompts the body to release its own stored hormone, rather than supplying
the hormone directly.
Why it matters: A secretagogue works within the body's existing feedback loops, so its
ceiling is set by what the gland can release. It is not interchangeable with administering
the hormone.
What the body does to a compound: absorption, distribution, metabolism, excretion.
Why it matters: PK is where most peptide claims fail quietly. A compound with a
demonstrated cellular effect and no route to reach the tissue at a relevant concentration
is a laboratory finding, not a therapy.
The fraction of an administered dose reaching systemic circulation intact, defined as
100% for intravenous administration.
Why it matters: Oral bioavailability for unmodified peptides is typically well under
1%, and often effectively zero. This single number invalidates most "oral peptide"
marketing.
The peak concentration a compound reaches in plasma after administration.
Why it matters: Many concentration-dependent adverse effects track Cmax rather than
total exposure, which is why slow-release formulations of the same molecule can be better
tolerated.
Total exposure over time, the integral of plasma concentration against time.
Why it matters: AUC, not peak, is usually what correlates with efficacy for sustained
effects. Two products with identical Cmax can differ several-fold in AUC.
The degradation of an absorbed compound by the gut wall and liver before it reaches
systemic circulation.
Why it matters: For peptides, degradation by digestive proteases usually happens before
first-pass metabolism even becomes relevant. Both barriers must be defeated for oral
delivery, and defeating them requires deliberate engineering.
The time for plasma concentration to fall by half. Roughly four to five half-lives are
needed for near-complete elimination.
Why it matters: Native peptide hormones often have half-lives of minutes. When a
product claims the effects of a hormone without the engineering that extends its life,
the pharmacokinetics are the claim to check first. Half-life is set largely by clearance,
and for small peptides clearance is dominated by the kidney, so impaired renal function
materially raises exposure, which is one specific reason unsupervised use by someone with
an undiagnosed condition carries risk.
Enzymatic cleavage of peptide bonds. In circulation, DPP-4, neprilysin and
aminopeptidases are among the main actors; DPP-4 removes two residues from the
N-terminus of many peptide hormones within minutes.
Why it matters: Resistance to proteolysis is engineered, not inherent. It is the
difference between a hormone that lasts minutes and an analogue that lasts days.
The selective endothelial barrier restricting passage from blood into brain tissue.
Most peptides cross poorly or not at all without a dedicated transport mechanism.
Why it matters: Nootropic and neuroprotective claims for peripherally administered
peptides require evidence of central exposure. That evidence is usually absent, and its
absence is rarely mentioned.
The capacity of an administered substance to provoke an immune response, including
anti-drug antibodies that neutralise it or cross-react with the body's own hormone.
Why it matters: Aggregates and impurities raise immunogenicity, which is one of the
concrete mechanisms by which a poorly manufactured peptide is more dangerous than a
well-manufactured one, not merely less effective.
The gap between the exposure that produces the desired effect and the exposure that
produces harm.
Why it matters: It is the number that makes a compound usable. It cannot be estimated
at all for compounds with no human dose-ranging data, which describes most substances sold
as research peptides.
The legally enforceable quality system governing medicine manufacture: facility control,
validated processes, documented batch records, retained samples, auditable release.
Why it matters: GMP is the difference between a product whose consistency is verifiable
and one whose consistency is asserted. Research-grade material is not made under it, and
"GMP-grade" on an unlicensed listing is an unverified marketing claim.
The standard method for separating peptides by hydrophobicity, reported as a chromatogram
with a percentage area for each peak.
Why it matters: Almost every purity figure you will see comes from this. Its meaning
depends entirely on whether the method was developed to resolve the specific impurities
that this synthesis produces.
Measurement of mass-to-charge ratio, used to confirm a peptide's molecular weight and,
in tandem (MS/MS), its sequence.
Why it matters: MS confirms identity in a way that HPLC cannot. A certificate with a
purity number but no mass spectrum has not demonstrated that the right molecule is in the
vial.
The proportion of the material that is the intended compound, conventionally the
target peak's share of total peak area by HPLC.
Why it matters: Purity is a statement about the sample analysed, and about the
impurities the method could see. It is not a statement about quantity, sterility or
activity.
The measured biological or quantitative content of active compound, determined by a
functional or reference-standard assay rather than by chromatographic area.
Why it matters: Purity and potency answer different questions. A 99% pure vial can
contain far less active compound than its label states, and only a potency assay reveals it.
A document reporting the analytical results for a specific manufactured batch.
Why it matters: A COA is only meaningful with a batch number matching your vial, a
test date, a named laboratory and the raw chromatogram. Without those it is a graphic,
and generic undated COAs are common.
The identifier tying a specific production run to its analytical records.
Why it matters: It is the entire basis of traceability. A COA whose batch number does
not match the vial in front of you documents someone else's material.
Analysis performed by a laboratory with no commercial interest in the result, commissioned
independently of the seller.
Why it matters: Self-reported testing has an obvious conflict of interest. Independent
testing of consumer-market peptides has repeatedly found discrepancies between label and
contents.
Lipopolysaccharide from the outer membrane of Gram-negative bacteria, which provokes fever
and inflammatory response. It survives sterilisation and is measured by the LAL assay.
Why it matters: Killing bacteria does not remove endotoxin. A product can be sterile
and still cause a severe febrile reaction when injected.
The absence of viable microorganisms, demonstrated by validated testing under aseptic
conditions.
Why it matters: Sterility is a property of a process, not something achievable
after the fact. Material not manufactured, filled and sealed as sterile cannot be made
sterile by the end user.
Traces of organic solvents from synthesis and purification remaining in the final product,
limited by pharmacopoeial thresholds for medicines.
Why it matters: These limits exist because some of the solvents involved are toxic.
Research-grade material is under no obligation to meet them.
The proportion of residual moisture in a lyophilised solid, measured by Karl Fischer
titration.
Why it matters: Water drives chemical degradation and is part of why mass on the label
overstates peptide content. Elevated moisture predicts a short shelf life regardless of
how pure the material was at release.
Performed outside a living organism: in cells, tissue or a test tube.
Why it matters: In vitro is where the great majority of peptide evidence stops. It
establishes that an interaction is possible, not that it happens in a person at reachable
concentrations.
Performed in a living organism, whether animal or human.
Why it matters: "In vivo" in a press release usually means rodents. Whether a rodent
result transfers to humans is an empirical question that most compounds never get asked.
A species or induced condition used to approximate a human disease.
Why it matters: Rodent models are often acute, artificial and young, while the human
condition is chronic and multifactorial. The translation failure rate from promising
animal data to human benefit is very high across all of drug development.
A study in which participants are allocated by chance to receive the intervention or a
comparator, so that the groups differ systematically only in the intervention.
Why it matters: Randomisation is what allows a causal claim. Without it, the people who
chose the intervention differ from those who did not in ways that no statistical adjustment
fully repairs. The comparator arm matters just as much: without a control group you cannot
separate the intervention's effect from natural recovery, seasonality, regression to the
mean and expectation. Most peptide "results" circulating online have no control at all.
Concealing group allocation. Single-blind conceals it from participants; double-blind from
participants and assessors both.
Why it matters: Unblinded assessment of subjective outcomes (pain, energy, mood,
recovery) reliably exaggerates effects, in both directions.
An inert comparator matched in appearance and administration to the active intervention.
Why it matters: Injections produce larger placebo responses than tablets, and
subjective outcomes produce larger ones than objective measures. Both conditions apply to
most peptide use.
The probability of observing data at least as extreme as the data obtained, if the null
hypothesis were true. Below 0.05 is conventionally called significant.
Why it matters: It is not the probability that the finding is true, and it says nothing
about effect size. A p-value of 0.049 in twelve people is not a result you should act on.
The range of values compatible with the data at a stated level of confidence, usually 95%.
Why it matters: More informative than a p-value, because it shows how large or small the
effect might plausibly be. A wide interval crossing zero means the study answered nothing.
The magnitude of a difference, expressed in units that allow comparison: mean difference,
risk ratio, standardised measures such as Cohen's d.
Why it matters: Statistical significance without effect size is empty. A change that is
real, reproducible and too small to notice is a common outcome.
A measurable marker used as a stand-in for the outcome that actually matters, a blood
level standing in for a symptom or a survival benefit.
Why it matters: Surrogates move more easily than real outcomes, and the history of
medicine includes drugs that improved the marker and worsened the patient.
A structured search of all studies meeting pre-set criteria, with a quantitative pooling of
results in a meta-analysis.
Why it matters: The strongest evidence tier available, and still limited by the
quality of what it pools. A meta-analysis of small, biased trials produces a precise,
biased answer.
A manuscript posted publicly before peer review (the assessment by independent
researchers that journals require before publication), typically on a server such as
bioRxiv or medRxiv.
Why it matters: Preprints are legitimate and useful, but they have not been checked by
anyone independent. Peer review is itself only a minimum filter, rarely involving
re-analysis of the data, and predatory journals sell its appearance without the substance.
Citing a preprint as though it were a peer-reviewed finding (common in peptide marketing)
misrepresents its status.
The tendency for positive results to be published while null results remain unpublished.
Why it matters: It means the published literature systematically overstates effects.
For compounds with few, small, enthusiastic studies, the true picture is almost always
weaker than the visible one.
Publicly recording a study's design, primary endpoint and analysis plan before data are
collected, on a registry such as ClinicalTrials.gov or ISRCTN.
Why it matters: It prevents the endpoint being switched to whichever measure happened to
reach significance. Absence of pre-registration for a trial reporting a positive result is a
meaningful weakness.
Any financial or professional interest that could plausibly influence the conduct or
reporting of research or commentary.
Why it matters: Selling the compound you are reviewing is a conflict, whether or not it
changes the conclusion. The convention is disclosure, so undisclosed selling is a specific
failure, not a technicality.
An account of one person's experience or outcome.
Why it matters: Genuinely valuable for flagging rare harms; near-worthless for
establishing benefit, because it has no control, no blinding and no denominator. Almost all
peptide "evidence" online is this.
The Medicines and Healthcare products Regulatory Agency, the UK regulator for medicines
and medical devices.
Why it matters: In the UK the MHRA determines what may lawfully be sold or supplied as
a medicine. It also runs the Yellow Card scheme, through which anyone may report a suspected
adverse reaction.
The US Food and Drug Administration, which approves medicines for marketing in the United
States.
Why it matters: The FDA maintains lists of substances it has assessed as unsuitable for
compounding and issues public alerts on unapproved injectables. Both are free to search and
directly relevant to compounds sold online.
The European Medicines Agency, which coordinates the scientific evaluation of medicines
across the EU.
Why it matters: EMA assessment reports are unusually detailed public documents,
including negative findings and unresolved concerns that do not appear in company
materials.
The licence permitting a medicine to be sold for a stated indication, granted only after
the regulator has assessed quality, safety and efficacy dossiers.
Why it matters: This is the concrete meaning of "approved". It is a specific legal
status for a specific product, indication and manufacturing process, not a general
endorsement of a molecule.
The US application permitting an unapproved substance to be given to humans in a clinical
trial.
Why it matters: An IND is not approval. "Currently in clinical trials" means a
regulator has permitted the question to be asked, not that any answer has come back.
Phase I assesses safety and pharmacokinetics, usually in small numbers; Phase II explores
efficacy and dose; Phase III tests efficacy against a comparator at scale; Phase IV follows
the product after approval.
Why it matters: Most compounds entering Phase I never reach approval. Citing a Phase I
result as evidence of benefit inverts what that phase is designed to measure.
A medicinal product with no marketing authorisation in the relevant territory. In the UK
these may be supplied to meet an individual patient's special clinical need (the "specials"
route) under defined conditions and professional responsibility.
Why it matters: This narrow clinical exemption is sometimes invoked to imply that
consumer sale of unapproved peptides is lawful. It does not apply to it.
A clinician prescribing an approved medicine outside its authorised indication, population
or route.
Why it matters: Legal, common and clinically legitimate, and entirely distinct from
using an unapproved research chemical. The two are frequently conflated to borrow the
legitimacy of the first.
A pharmacy preparing a medicine for an individual patient where no suitable licensed
product exists. In the US, 503A pharmacies compound per prescription and 503B outsourcing
facilities produce larger batches under stricter oversight.
Why it matters: Compounded products are not reviewed for safety or efficacy before
sale, and quality has varied widely in practice. Regulators have issued repeated alerts
about compounded and falsified injectable peptide products.
A labelling designation meaning material is supplied for laboratory use and not for
diagnostic or human application.
Why it matters: Read plainly, it is a legal shield. It allows unapproved compounds to be
sold to consumers while disclaiming the human use everyone involved anticipates, and it
carries no requirement for sterility, pharmaceutical-grade manufacture or accurate labelling.
It is a statement about liability, not about quality.
A product deliberately misrepresenting its identity, composition, source or history.
Why it matters: Falsified injectable peptide products have been seized in multiple
countries, including devices presented as licensed pens. Purchase from an unlicensed source
means the contents are unverified by anyone.
The systematic monitoring of adverse effects after a medicine reaches the market, the
Yellow Card scheme in the UK, MedWatch in the US.
Why it matters: It is how rare harms are eventually detected. Substances used outside
the licensed system generate no such signal, so their harms accumulate invisibly.
The World Anti-Doping Agency's annually updated list of substances and methods banned in
sport, including growth hormone secretagogues, GH-releasing peptides and several other
peptide classes.
Why it matters: Many peptides marketed to athletes are prohibited, several at all times
rather than in competition only. The list is published free, and "not detectable" is a
claim that has aged badly for essentially every compound it has been made about.
*BioRx is an independent, non-commercial education library. We sell nothing and have no
commercial relationship with any manufacturer or vendor. Corrections:
see the about page.*
Try a shorter search.